Browse

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.

Medicare proposes to reduce payments to hospitals for certain drugs and imaging services.